Short answer
Tonix Pharmaceuticals Holding Corp. (TNXP) filed an 8-K current report with the SEC on October 15, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events). Preliminary Q3 2026 TONMYA net revenue estimated at $14.0 million to $15.0 million.
Tonix Pharmaceuticals Holding Corp. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Preliminary Q3 2026 TONMYA net revenue estimated at $14.0 million to $15.0 million
- Cash and cash equivalents approximately $162.8 million as of September 30, 2026
- Revenue range provides an early read on TONMYA commercialization and near-term liquidity
- Results remain unaudited and subject to quarter-end adjustments, potentially materially different from estimates
Item 8.01 · Other Events
- Item 8.01 incorporates the Item 2.02 earnings disclosure by reference
- Investor focus remains on the separate Item 2.02 exhibit for financial results or operating updates
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tonix Pharmaceuticals Holding Corp. 8-K filings
Get the next TNXP 8-K as it lands
Follow TNXP for push alerts, or ask the research agent what this filing means.